Role of Niacin in Current Clinical Practice: A Systematic Review

American Journal of Medicine

Volumn 130, Issue 2, 2017, Pages 173-187

  Garg, Aakash ^a   Sharma, Abhishek ^b   Krishnamoorthy, Parasuram ^c   Garg, Jalaj ^d   Virmani, Deepti ^e   Sharma, Toishi ^f   Stefanini, Giulio ^g   Kostis, John B ^h   Mukherjee, Debabrata ⁱ   Sikorskaya, Ekaterina ^j  

^a SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

^d LEHIGH VALLEY HOSPITAL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^j BROOKLYN HOSPITAL CENTER   (United States)

more..

Author keywords

Cardiovascular risk; High density lipoprotein cholesterol; Niacin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ANTILIPEMIC AGENT;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CINAHL; CLINICAL OUTCOME; CLINICAL PRACTICE; COCHRANE LIBRARY; CORONARY ARTERY RECANALIZATION; DISEASE ASSOCIATION; DRUG EFFECT; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW RISK PATIENT; MEDLINE; META ANALYSIS; MORTALITY RATE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; WEB OF SCIENCE; BLOOD; CARDIOVASCULAR DISEASES; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN; TREATMENT OUTCOME;

EID: 85007406957     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.07.038     Document Type: Article

References (55)

1. 1 Executive summary: heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131:4 (2015), 434–441.
2. 2 Castelli, W.P., Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 4:suppl (1988), 5A–10A.
3. 3 Pekkanen, J., Linn, S., Heiss, G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322:24 (1990), 1700–1707.
4. 4 Di Angelantonio, E., Sarwar, N., Perry, P., Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
5. 5 Andersson, C., Lyass, A., Vasan, R.S., Massaro, J.M., D'Agostino, R.B. Sr., Robins, S.J., Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J 168:6 (2014), 878–883.
6. 6 Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:20 (1998), 1615–1622.
7. 7 Cannon, C.P., Braunwald, E., McCabe, C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:15 (2004), 1495–1504.
8. 8 Cholesterol Treatment Trialist (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
9. 9 Baigent, C., Keech, A., Kearney, P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:9493 (2005), 1267–1278.
10. 10 American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 suppl 2 (2014), S1–S45.
11. 11 Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol 8:5 (2014), 473–488.
12. 12 Boekholdt, S.M., Hovingh, G.K., Mora, S., et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64:5 (2014), 485–494.
13. 13 de Lemos, J.A., Blazing, M.A., Wiviott, S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004), 1307–1316.
14. 14 Barter, P., Gotto, A.M., LaRosa, J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:13 (2007), 1301–1310.
15. 15 Jafri, H., Alsheikh-Ali, A.A., Karas, R.H., Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 153:12 (2010), 800–808.
16. 16 Acharjee, S., Boden, W.E., Hartigan, P.M., et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol 62:20 (2013), 1826–1833.
17. 17 Goldbourt, U., Yaari, S., Medalie, J.H., Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17 (1997), 107–113.
18. 18 Stampfer, M.J., Sacks, F.M., Salvini, S., Willett, W.C., Hennekens, C.H., A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325:6 (1991), 373–381.
19. 19 Rubins, H.B., Robins, S.J., Collins, D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999), 410–418.
20. 20 Kamanna, V.S., Kashyap, M.L., Mechanism of action of niacin. Am J Cardiol 101 (2008), 20B–26B.
21. 21 The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975), 360–381.
22. 22 Taylor, A.J., Sullenberger, L.E., Lee, H.J., Lee, J.K., Grace, K.A., Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004), 3512–3517.
23. 23 A.I.M.-H.I.G.H. Investigators, Boden, W.E., Probstfield, J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:24 (2011), 2255–2267.
24. 24 HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:3 (2014), 203–212.
25. 25 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(6), 2009, e1000097.
26. 26 Kane, J.P., Malloy, M.J., Ports, T.A., Phillips, N.R., Diehl, J.C., Havel, R.J., Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 (1990), 3007–3012.
27. 27 Blankenhorn, D.H., Nessim, S.A., Johnson, R.L., Sanmarco, M.E., Azen, S.P., Cashin-Hemphill, L., Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987), 3233–3240.
28. 28 Brown, G., Albers, J.J., Fisher, L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:19 (1990), 1289–1298.
29. 29 Whitney, E.J., Krasuski, R.A., Personius, B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005), 95–104.
30. 30 Carlson, L.A., Rosenhamer, G., Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988), 405–418.
31. 31 Brown, B.G., Xue-Qiao, Z., Chait, A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001), 1583–1592.
32. 32 Taylor, A.J., Villines, T.C., Stanek, E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361:22 (2009), 2113–2122.
33. 33 Guyton, J.R., Brown, B.G., Fazio, S., Polis, A., Tomassini, J.E., Tershakovec, A.M., Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol, 51, 2008, 1564e72.
34. 34 Sang, Z.C., Wang, F., Zhou, Q., et al. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chin Med J (Engl) 122 (2009), 1615–1620.
35. 35 LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:14 (2005), 1425–1435.
36. 36 Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., Dawber, T.R., High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62 (1977), 707–714.
37. 37 Ray, K.K., Cannon, C.P., Cairns, R., Morrow, D.A., Ridker, P.M., Braunwald, E., Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29:3 (2009), 424–430.
38. 38 Ridker, P.M., Genest, J., Boekholdt, S.M., et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376:9738 (2010), 333–339.
39. 39 Canner, P.L., Berge, K.G., Wenger, N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986), 1245–1255.
40. 40 Duggal, J.K., Singh, M., Attri, N., et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 15 (2010), 158–166.
41. 41 Bruckert, E., Labreuche, J., Amarenco, P., Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:2 (2010), 353–361.
42. 42 Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.
43. 43 Lavigne, P.M., Karas, R.H., The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61:4 (2013), 440–446.
44. 44 Puri, R., Nissen, S.E., Shao, M., et al. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: implications for coronary atheroma progression and cardiovascular events. Eur J Prev Cardiol 23:5 (2016), 474–485.
45. 45 Mora, S., Glynn, R.J., Ridker, P.M., High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128 (2013), 1189–1197.
46. 46 Otvos, J.D., Collins, D., Freedman, D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006), 1556–1563.
47. 47 Khera, A.V., Patel, P.J., Reilly, M.P., Rader, D.J., The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 62:20 (2013), 1909–1910.
48. 48 Rohatgi, A., Khera, A., Berry, J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:25 (2014), 2383–2393.
49. 49 El Khoury, P., Waldmann, E., Huby, T., et al. Extended-release niacin/laropiprant improves overall efficacy of postprandial reverse cholesterol transport. Arterioscler Thromb Vasc Biol 36:2 (2016), 285–294.
50. 50 Ronsein, G.E., Hutchins, P.M., Isquith, D., et al. Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects. Arterioscler Thromb Vasc Biol 36:2 (2016), 404–411.
51. 51 Boekholdt, S.M., Arsenault, B.J., Hovingh, G.K., et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128:14 (2013), 1504–1512.
52. 52 Digby, J.E., McNeill, E., Dyar, O.J., Lam, V., Greaves, D.R., Choudhury, R.P., Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 209 (2010), 89–95.
53. 53 Bots, M.L., Visseren, F.L., Evans, G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007), 153–160.
54. 54 ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:17 (2010), 1563–1574.
55. 55 Schwartz, G.G., Olsson, A.G., Abt, M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:22 (2012), 2089–2099.